Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders
ATHEROSCLEROSIS(2020)
摘要
Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipi- demias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non- alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.
更多查看译文
关键词
Dyslipidemias,Liver organoids,Regenerative medicine,Drug testing,Non-alcohol fatty liver disease
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要